Odyssey Therapeutics raises USD 304 million in upsized Nasdaq IPO at USD 18 share price

Odyssey Therapeutics

Odyssey Therapeutics

ODTX

0.00
  • Jeito Capital participated in portfolio company Odyssey Therapeutics’ upsized IPO on Nasdaq, raising USD 304 million at USD 18 per share.
  • Odyssey began trading May 8 under ticker ODTX; offering included 15,500,000 shares in IPO plus 1,388,889 shares sold in concurrent private placement to affiliate of TPG Life Sciences Innovations.
  • Jeito investment followed its participation in Odyssey’s USD 213 million Series D financing in September 2025.
  • Proceeds earmarked to advance OD-001 in ulcerative colitis Phase 2a combination trial plus Phase 2b monotherapy trial; funding also supports OD-002 program through Phase 1/2a.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jeito Capital SAS published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.